7-33533991-T-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 3P and 9B. PM2PP3BP4_StrongBP6BS1
The NM_198428.3(BBS9):c.2336T>A(p.Leu779Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00031 in 1,614,250 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0017 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00016 ( 0 hom. )
Consequence
BBS9
NM_198428.3 missense
NM_198428.3 missense
Scores
7
6
6
Clinical Significance
Conservation
PhyloP100: 7.45
Genes affected
BBS9 (HGNC:30000): (Bardet-Biedl syndrome 9) This gene is downregulated by parathyroid hormone in osteoblastic cells, and therefore is thought to be involved in parathyroid hormone action in bones. The exact function of this gene has not yet been determined. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jan 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
Multiple lines of computational evidence support a deleterious effect 7: AlphaMissense, BayesDel_noAF, Cadd, Eigen, FATHMM_MKL, PROVEAN, REVEL [when BayesDel_addAF, max_spliceai, M_CAP, MetaRNN, MutationTaster was below the threshold]
BP4
Computational evidence support a benign effect (MetaRNN=0.04413256).
BP6
Variant 7-33533991-T-A is Benign according to our data. Variant chr7-33533991-T-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 242248.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=2}.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00171 (260/152356) while in subpopulation AFR AF= 0.00594 (247/41578). AF 95% confidence interval is 0.00533. There are 1 homozygotes in gnomad4. There are 131 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS9 | NM_198428.3 | c.2336T>A | p.Leu779Gln | missense_variant | 21/23 | ENST00000242067.11 | NP_940820.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS9 | ENST00000242067.11 | c.2336T>A | p.Leu779Gln | missense_variant | 21/23 | 1 | NM_198428.3 | ENSP00000242067.6 |
Frequencies
GnomAD3 genomes AF: 0.00171 AC: 260AN: 152238Hom.: 1 Cov.: 32
GnomAD3 genomes
AF:
AC:
260
AN:
152238
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000477 AC: 120AN: 251484Hom.: 1 AF XY: 0.000375 AC XY: 51AN XY: 135918
GnomAD3 exomes
AF:
AC:
120
AN:
251484
Hom.:
AF XY:
AC XY:
51
AN XY:
135918
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000164 AC: 240AN: 1461894Hom.: 0 Cov.: 30 AF XY: 0.000143 AC XY: 104AN XY: 727248
GnomAD4 exome
AF:
AC:
240
AN:
1461894
Hom.:
Cov.:
30
AF XY:
AC XY:
104
AN XY:
727248
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00171 AC: 260AN: 152356Hom.: 1 Cov.: 32 AF XY: 0.00176 AC XY: 131AN XY: 74510
GnomAD4 genome
AF:
AC:
260
AN:
152356
Hom.:
Cov.:
32
AF XY:
AC XY:
131
AN XY:
74510
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
29
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
80
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 03, 2024 | Reported in the heterozygous state in an individual with Bardet-Biedl syndrome (BBS) who was not found to have a second BBS9 variant but did harbor a variant in another BBS-related gene; however, familial segregation information was not provided for either variant (PMID: 21052717); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; In silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; Also known as p.L781Q; This variant is associated with the following publications: (PMID: 21052717) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jul 28, 2017 | - - |
not specified Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 19, 2022 | DNA sequence analysis of the BBS9 gene demonstrated a sequence change, c.2336T>A, in exon 21 that results in an amino acid change, p.Leu779Gln. This sequence change has been described in the gnomAD database with a frequency of 0.66% in the African/African American subpopulation and includes one individual homozygous for this variant (dbSNP rs142434516). The p.Leu779Gln change affects a highly conserved amino acid residue located in a domain of the BBS9 protein that is not known to be functional. The p.Leu779Gln substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change has been previously described in an individual with Bardet-Biedl syndrome in the heterozygous state, however a second variant in BBS9 or another BBS-related gene was not identified (PMID: 21052717). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Leu779Gln change remains unknown at this time. - |
Bardet-Biedl syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
T;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D
Sift4G
Uncertain
D;D;D;D
Polyphen
D;D;D;.
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at